MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Clinical trials for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PERIPHERAL NERVE SHEATH TUMOR trials appear
Sign up with your email to follow new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets cancer spread in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental drug TURALIO takes on tough childhood cancers in early trial
Disease control Recruiting nowThis early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for rare cancers: experimental drug ADCT-701 enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC